Effect of thrombopoietin on proliferation of blasts from patients with myelodysplastic syndromes

Stem Cells

Volumn 18, Issue 2, 2000, Pages 112-119

  Luo, Shan Shun ^a   Ogata, Kiyoyuki ^a   Yokose, Norio ^a   Kato, Takashi ^b   Kazuo, Dan ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b KIRIN BREWERY CO LTD   (Japan)

Author keywords

Blast proliferation; Myelodysplastic syndromes; Thrombopoietin

Indexed keywords

CYTOKINE; LACTATE DEHYDROGENASE; THROMBOPOIETIN;

ADULT; AGED; ARTICLE; BLAST CELL; CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MEGAKARYOPOIESIS; MYELODYSPLASTIC SYNDROME; THROMBOCYTOPOIESIS;

EID: 0034024416     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.18-2-112     Document Type: Article

References (30)

1. Hofmann WK, Ottmann OG, Ganser A et al. Myelodysplastic syndromes: clinical features. Semin Hematol 1996;33:177-185.
2. Negrin RS, Haeuber DH, Nagler A et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 1990;76:36-43.
3. Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood 1995;86:419-431.
4. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci USA 1994;91:11104-11108.
5. Debili N, Wendling F, Cosman D et al. The Mpl receptor is expressed in the megakaryocytic lineage from late progenitors to platelets. Blood 1995;85:391-401.
6. Debili N, Wendling F, Katz A et al. The Mpl-ligand or thrombopoietin or megakaryocyte growth and differentiative factor has both direct proliferative and differentiative activities on human megakaryocyte progenitors. Blood 1995;86:2516-2525.
7. Takeshita A, Shinjo K, Naito K et al. Amount of mpl on bone marrow haemopoietic precursor cells from healthy volunteers and patients with refractory anaemia. Br J Haematol 1997;99:746-755.
8. Albitar M, Manshouri T, Kantarjian H et al. Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia. Leuk Res 1999;23:63-69.
9. Takeshita A, Shinjo K, Izumi M et al. Quantitative expression of thrombopoietin receptor on leukaemia cells from patients with acute myeloid leukaemia and acute lymphoblastic leukaemia. Br J Haematol 1998;100:283-290.
10. Wetzler M, Baer MR, Bernstein SH et al. Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy. J Clin Oncol 1997;15:2262-2268.
11. Tokunaga Y, Miyamoto T, Okamura T et al. Effect of thrombopoietin on proliferation of blasts from CD7-positive acute myelogenous leukaemia. Br J Haematol 1998;102:1232-1240.
12. Bouscary D, Preudhomme C, Ribrag V et al. Prognostic value of c-mpl expression in myelodysplastic syndromes. Leukemia 1995;9:783-788.
13. Fonlenay RM, Dupont JM, Picard F et al. Analysis of megakaryocyte growth and development factor (thrombopoietin) effects on blast cell and megakaryocyte growth in myelodysplasia. Leuk Res 1998;22:527-535.
14. Tamura H, Ogata K, Luo S et al. Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes. Br J Haematol 1998;103:778-784.
15. Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:189-199.
16. Ogata K, Fujii H, Yokose N et al. Defective natural killer (NK) cell mediated cytotoxicity does not imply clonal involvement of NK cells in myelodysplastic syndromes. Br J Haematol 1994;87:396-398.
17. Ogata K, An E, Kamikubo K et al. Cell cycle modulation by hematopoietic growth factors in myelodysplastic syndromes: analysis by three-color flow cytometry. Exp Hematol 1997;25:8-18.
18. An E, Ogata K, Kamikubo K et al. Cell cycle analysis of blasts in patients with myelodysplastic syndromes who received granulocyte colony-stimulating factor. In: Nomura T, Yoshida Y, eds. Myelodysplastic Syndromes: Advances in Research and Treatment. Amsterdam: Elsevier Science, 1998:361-368.
19. Tafuri A, Andreeff M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 1990;4:826-834.
20. Raza A, Maheshwari Y, Mandava N et al. Cell cycle and drug sensitivity studies of leukemic cells that appear relevant in determining response to chemotherapy in acute nonlymphocytic leukemia. Semin Oncol 1987;14(suppl 1):217-225.
21. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
22. Matsumura I, Ikeda H, Kanakura Y. The effects of thrombopoietin on the growth of acute myeloblastic leukemia cells. Leuk Lymphoma 1996;23:533-538.
23. Komura E, Matsumura T, Kato T et al. Thrombopoietin in patients with hepatoblastoma. STEM CELLS 1998;16:329-333.
24. Greenberg P, Cox C, LeBeau MM et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
25. Papayannopoulou T, Brice M, Farrer D et al. Insights into the cellular mechanisms of erythropoietin-thrombopoietin synergy. Exp Hematol 1996;24:660-669.
26. Era T, Takahashi T, Sakai K et al. Thrombopoietin enhances proliferation and differentiation of murine yolk sac erythroid progenitors. Blood 1997;89:1207-1213.
27. Carver MK, Broxmeyer HE, Luoh SM et al. Low levels of erythroid and myeloid progenitors in thrombopoietin- and c-mpl-deficient mice. Blood 1996;88:803-808.
28. Toba K, Winton EF, Koike T et al. Simultaneous three-color analysis of the surface phenotype and DNA-RNA quantitation using 7-amino actinomycin D and pyronin Y. J Immunol Methods 1995;182:193-207.
29. Oertel J, Kleiner S, Huhn D. Immunotyping of blasts in refractory anaemia with excess of blasts. Br J Haematol 1993;84:305-309.
30. Oster W, Cicco NA, Klein H et al. Participation of the cytokines interleukin 6, tumor necrosis factor-α, and interleukin 1-β secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. J Clin Invest 1989; 84:451-457.